Tao Sun
Liaoning Cancer Hospital & Institute · Beijing Tiantan Hospital · Shanghai Eye Diseases Prevention & Treatment Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Tao Sun as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:59 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07657130 · Optimal Application Timing of ADC Drugs for Advanced Breast CancerLiaoning Cancer Hospital & Institute · recruiting · Breast Cancer Females · principal investigator
- Early Ph1NCT06396481 · Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant GliomaBeijing Tiantan Hospital · not yet recruiting · GBM, DIPG Brain Tumor, Medulloblastoma · principal investigator
- Ph4NCT06305143 · Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic RetinopathyShanghai Eye Disease Prevention and Treatment Center · active not recruiting · Diabetic Macular Edema · study chair
- N/ANCT06232616 · Vitrectomy Combined With Intravitreal Dexamethasone Implant for Idiopathic Epiretinal Membrane With Macular OedemaShanghai Eye Disease Prevention and Treatment Center · enrolling by invitation · Epiretinal Membrane · study chair
- Ph2NCT05244993 · AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast CancerLiaoning Cancer Hospital & Institute · unknown · Breast Neoplasm Female · principal investigator
- Ph3NCT04400695 · A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2RemeGen Co., Ltd. · recruiting · Breast Cancer · principal investigator
- Ph2NCT03932526 · Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast CancerLiaoning Cancer Hospital & Institute · unknown · Triple-negative Breast Cancer · principal investigator
- Ph2NCT03562390 · Irinotecan for Advanced and Metastatic Breast CancerLiaoning Cancer Hospital & Institute · unknown · Breast Cancer · principal investigator
- Ph2NCT02030678 · A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast CancerLiaoning Cancer Hospital & Institute · unknown · Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:59 UTC. The ranking covers the 200 most relevant of 62 PubMed records, and a shared surname and initials can bring in a namesake. All 62 on PubMed
- 2,392 citationsRCR 180.8
- 358 citationsRCR 18.5
- 227 citationsRCR 7.6
- 153 citationsRCR 6.8
- 146 citationsRCR 9.2
- Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial.Nat Med · 2024134 citationsRCR 14.2
- 108 citationsRCR 8.6
- 107 citationsRCR 9.1
- 88 citationsRCR 9.5
- Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.Eur J Cancer · 201971 citationsRCR 2.3